Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16223362 
Wingate AD, Campbell DG, Peggie M, Arthur JS (2006) Nur77 is phosphorylated in cells by RSK in response to mitogenic stimulation. Biochem J 393, 715-24 16223362
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (human)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
NGF increase

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
EGF increase
H-89 phorbol ester inhibit treatment-induced increase
H-89 EGF inhibit treatment-induced increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Ro31-8220 EGF inhibit treatment-induced increase
wortmannin phorbol ester no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
wortmannin EGF no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
SB203580 phorbol ester no effect upon treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
U0126 phorbol ester inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
PD184352 EGF inhibit treatment-induced increase
NGF increase

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
EGF increase
H-89 phorbol ester inhibit treatment-induced increase
H-89 EGF inhibit treatment-induced increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Ro31-8220 EGF inhibit treatment-induced increase
wortmannin phorbol ester no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
wortmannin EGF no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
SB203580 phorbol ester no effect upon treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
U0126 phorbol ester inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
PD184352 EGF inhibit treatment-induced increase
NGF increase

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
EGF increase
H-89 phorbol ester inhibit treatment-induced increase
H-89 EGF inhibit treatment-induced increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Ro31-8220 EGF inhibit treatment-induced increase
wortmannin phorbol ester no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
wortmannin EGF no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
SB203580 phorbol ester no effect upon treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
U0126 phorbol ester inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
PD184352 EGF inhibit treatment-induced increase
NGF increase

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
EGF increase
H-89 phorbol ester inhibit treatment-induced increase
H-89 EGF inhibit treatment-induced increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Ro31-8220 EGF inhibit treatment-induced increase
wortmannin phorbol ester no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
wortmannin EGF no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
SB203580 phorbol ester no effect upon treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
U0126 phorbol ester inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
PD184352 EGF inhibit treatment-induced increase
NGF increase

S21-p - GSK3A (human)
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat

S9-p - GSK3B (human)
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat

S347-p - NR4A2 (human)
Orthologous residues
NR4A2 (human): S347‑p, NR4A2 (mouse): S347‑p, NR4A2 (rat): S347‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
EGF increase
H-89 phorbol ester inhibit treatment-induced increase
H-89 EGF inhibit treatment-induced increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Ro31-8220 EGF inhibit treatment-induced increase
wortmannin phorbol ester no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
wortmannin EGF no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
SB203580 phorbol ester no effect upon treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
U0126 phorbol ester inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
PD184352 EGF inhibit treatment-induced increase

S376-p - NR4A3 (human)
Orthologous residues
NR4A3 (human): S376‑p, NR4A3 iso2 (human): S376‑p, NR4A3 (mouse): S377‑p, NR4A3 (rat): S378‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
EGF increase
H-89 phorbol ester inhibit treatment-induced increase
H-89 EGF inhibit treatment-induced increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Ro31-8220 EGF inhibit treatment-induced increase
wortmannin phorbol ester no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
wortmannin EGF no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
SB203580 phorbol ester no effect upon treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
U0126 phorbol ester inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
PD184352 EGF inhibit treatment-induced increase

T180-p - P38A (human)
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
EGF increase
NGF increase

Y182-p - P38A (human)
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
EGF increase
NGF increase

T359-p - p90RSK (human)
Orthologous residues
p90RSK (human): T359‑p, p90RSK iso2 (human): T368‑p, p90RSK (mouse): T348‑p, p90RSK iso3 (mouse): , p90RSK (rat): T359‑p, p90RSK (chicken): T377‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
NGF increase

S354-p - Nur77 (mouse)
Orthologous residues
Nur77 (human): S351‑p, Nur77 (mouse): S354‑p, Nur77 (rat): S350‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse, rat
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE RSK2 (human)
KINASE MSK1 (human)
KINASE p90RSK (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 no change compared to control
anisomycin no change compared to control
phorbol ester increase
EGF increase
H-89 phorbol ester inhibit treatment-induced increase
H-89 EGF inhibit treatment-induced increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Ro31-8220 EGF inhibit treatment-induced increase
wortmannin phorbol ester no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
wortmannin EGF no effect upon treatment-induced increase Slight decrease in NR4A2, not in others
SB203580 phorbol ester no effect upon treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
U0126 phorbol ester inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
PD184352 phorbol ester inhibit treatment-induced increase
PD184352 EGF inhibit treatment-induced increase
phorbol ester increase Not seen in PDK1 -/- cells or cells expressing L155E PDK1 mutants
NGF increase
Downstream Regulation
 Effect of modification (function):  activity, inhibited
 Comments:  Overlay assays are suggestive 14-3-3 binding due to PMA-stimulated phosphorylation (not confirmed to a specific site in Nur77 but correlated with pS354 signal and region around S354 has homology to 14-3-3 binding sites). Could not be confirmed in co-IP experiments. Mutation of S354A increaased transcription and S354D decreased transcription.


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.